Zacks Research Analysts Increase Earnings Estimates for BIO

Key Points

• Zacks Research raised Bio-Rad’s Q1 2028 EPS estimate to $2.26 from $1.96, while maintaining a “Hold” rating. The consensus full-year earnings estimate is $9.28 per share.
• Analysts have generally remained cautious despite higher price targets: one analyst rates the stock a Buy and four rate it Hold, producing a consensus “Hold” rating and average price target of $343.33.
• Bio-Rad recently exceeded quarterly expectations, reporting $2.62 EPS versus the $1.75 consensus and revenue of $651 million versus $623.99 million expected. Institutional investors own 65.24% of the company, with several major firms increasing their stakes.

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities research analysts at Zacks Research raised their Q1 2028 earnings estimates for Bio-Rad Laboratories in a research report issued on Tuesday, August 25th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.26 per share for the quarter, up from their prior estimate of $1.96. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $9.28 per share.

A number of other equities analysts also recently commented on the company. Royal Bank Of Canada lifted their price target on Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded Bio-Rad Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Finally, Citigroup boosted their price target on Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $343.33.

Bio-Rad Laboratories Price Performance

BIO opened at $391.29 on Thursday. The company has a 50-day moving average of $322.01 and a 200-day moving average of $294.60. The company has a market capitalization of $10.46 billion, a P/E ratio of 47.43 and a beta of 1.06. Bio-Rad Laboratories has a 1-year low of $236.73 and a 1-year high of $393.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.33 and a current ratio of 3.14.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.87. Bio-Rad Laboratories had a net margin of 8.59% and a return on equity of 3.54%. The firm had revenue of $651.00 million for the quarter, compared to analysts' expectations of $623.99 million. During the same period in the prior year, the company posted $2.61 earnings per share. The firm's quarterly revenue was down .1% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in shares of Bio-Rad Laboratories by 25.2% in the 1st quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company's stock worth $7,382,000 after acquiring an additional 6,100 shares during the period. Goldman Sachs Group Inc. boosted its stake in Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company's stock valued at $25,575,000 after purchasing an additional 32,874 shares during the period. Empowered Funds LLC grew its position in Bio-Rad Laboratories by 14.8% in the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company's stock worth $377,000 after purchasing an additional 199 shares during the last quarter. Jane Street Group LLC grew its position in Bio-Rad Laboratories by 95.3% in the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company's stock worth $9,105,000 after purchasing an additional 18,239 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Bio-Rad Laboratories by 13.5% in the second quarter. Cetera Investment Advisers now owns 2,192 shares of the medical research company's stock valued at $529,000 after purchasing an additional 260 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source